Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a multi-agent chemotherapy regimen composed of five cytotoxic drugs: - Ifosfamide (an alkylating agent) - Pirarubicin (an anthracycline antibiotic, structurally related to doxorubicin) - Etoposide (a topoisomerase II inhibitor) - Carboplatin (a platinum-based DNA crosslinker) - Paclitaxel (a microtubule stabilizer) Each component has a distinct mechanism of action targeting rapidly dividing cancer cells. This combination is not a standard named regimen but represents an intensive, broad-spectrum chemotherapeutic approach. Regimens containing similar agents—such as ICE-T or TICE—are used in the treatment of various solid tumors and hematologic malignancies, including germ cell tumors, breast cancer, sarcomas, and lung cancers[1][2][3]. The inclusion of pirarubicin instead of the more common doxorubicin is less typical but may be chosen for specific clinical scenarios.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ifosfamide + pirarubicin + etoposide + carboplatin + paclitaxel.